Core Insights - Arcellx Inc. presented new data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma at the 2025 ASH Annual Meeting [1][2] Data Summary - The study included 117 patients with a median follow-up of 15.9 months, all receiving a single infusion of anito-cel at a target dose of 115×10^6 CAR+ viable T cells [2] - The overall response rate (ORR) was 96% (112/117), with a complete response/stringent complete response (CR/sCR) rate of 74% (86/117) and a very good partial response or higher (≥VGPR) rate of 88% (103/117) [3] - Among those evaluable for minimal residual disease (MRD) testing, 95% (91/96) achieved overall MRD negativity, and 83% (54/65) sustained MRD negativity for over 6 months [3] Survival Rates - Six-month progression-free survival (PFS) and overall survival (OS) rates were 93.1% and 95.7%, respectively, with median PFS and OS not yet reached [4] - Twelve-month PFS and OS rates were 82.1% and 94.0%, while 18-month rates were 67.4% and 88.0%, and 24-month rates were 61.7% and 83.0% [7] Safety Profile - No delayed or non-ICANS neurotoxicities have been observed in patients dosed more than 12 months ago, including no cases of Parkinsonism or Guillain-Barré syndrome [4] Commercial Outlook - The company anticipates the commercial launch of anito-cel in 2026 [4] Analyst Commentary - Analysts from William Blair and Needham expressed confidence in anito-cel's best-in-class profile and reiterated a Buy rating for Arcellx, maintaining a price target of $105 [5] - Arcellx shares increased by 10.12% to $76.59 at the time of publication [5]